Address	Shirokanedai Usui Building, 6/F Tokyo Tokyo 108 Japan
Employees	-
Website	http://www.ribomic.com/
Updated	07/08/2019
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes RiboART system, a platform technology essentially applicable to any target proteins, and not limited to disease. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.